Douglas J Swirsky has bought stock on 2 days since Sep 2021

Douglas J. Swirsky is a corporate finance executive and board director in the life sciences sector, currently serving as Chief Financial Officer (CFO) of MaxCyte, Inc. (Nasdaq: MXCT), where he was appointed in March 2023 to also serve as principal accounting officer.( At MaxCyte, a cell‑engineering focused company enabling the discovery, development, and commercialization of next‑generation cell‑based therapeutics, he oversees the company’s global finance and capital strategy and is involved in supporting its strategic initiatives.( He has also been reported as an insider trading MaxCyte common stock in his capacity as CFO.(

Swirsky brings more than two decades of experience in healthcare and biopharmaceutical finance and leadership, including roles as CFO and Treasurer of AavantiBio, Inc. until its acquisition by Solid Biosciences in 2022, President and CEO (and earlier President and CFO) of Rexahn Pharmaceuticals, and President and CEO of GenVec, Inc., after initially joining GenVec as CFO.( Before his operating-company leadership roles, he was Managing Director and Head of Life Sciences Investment Banking at Stifel Nicolaus and held investment banking positions at Morgan Stanley, UBS, PaineWebber, and Legg Mason.( Swirsky currently serves as Chairman of the Board of Cellectar Biosciences, Inc. (Nasdaq: CLRB) and has previously served on the boards of several other life sciences companies.( He is a certified public accountant, a CFA® charterholder, and NACD Directorship Certified, and holds a B.S. in Business Administration from Boston University and an M.B.A. from the Kellogg School of Management at Northwestern University.(

Written by Perplexity from public sources.